An update to our antibacterial report with 2018/2019 Q1 data is now available online. This is available to our stakeholders only (username and password required). Access is via the Prescribing Analysis Reports section of this site (Under the Prescribing Analysis Reports menu, click on the 'Therapeutic' menu item followed by the ‘Antibacterial’ heading).
Published: Fri, 19 Oct 2018 13:09:51 +0000
Our Cost Comparison Charts and Switch Saving Calculators for October 2018 are now available online. The latest Excel, Word and PDF versions of the Cost Comparison Charts are available to our stakeholders only (user and password required). The charts are located here.
The Switch Saving Calculators are also available to stakeholders only. Access is via the Prescribing Analysis Reports menu, under the Cost Impact and Savings submenu item.
Published: Thu, 18 Oct 2018 10:38:42 +0000
Published: Wed, 17 Oct 2018 15:55:00 +0000
Updates to our cardiovascular, dementia, diabetes and respiratory reports with 2018/2019 Q1 data are now available online. These are available to our stakeholders only (username and password required). Access is via the Prescribing Analysis Reports section of this site (Under the Prescribing Analysis Reports menu, click on the 'Therapeutic' menu item followed by the relevant BNF heading)
Published: Wed, 03 Oct 2018 15:51:58 +0000
The new Safer Medication Use bulletin on Ethanol in oral medicines for children is now available to stakeholders. These publications jointly produced by the RDTC and the Yellow Card Centre Northern and Yorkshire are aimed at all prescribers, nurses, pharmacists, Drug and Therapeutics Committees and Medicine Optimisation Groups. They can also be used by clinical governance and non-medical prescribing leads to inform prescribing policy decisions and risk management strategies.
Published: Mon, 01 Oct 2018 14:03:20 +0000
Two medicines in practice documents review the cardiovascular outcomes associated with the SGLT2 inhibitors, and the GLP1 receptor agonists. These publication are specifically designed to support stakeholder Medicines Management services to maximise health gains through the optimum use of medicines by influencing and changing prescribing behaviour. Additionally, a new drug evaluation of Semaglutide in the treatment of type 2 diabetes provides a concise, structured evaluation of the efficacy, safety, cost and potential place in therapy for this new GLP1 receptor agonist.
Published: Fri, 28 Sep 2018 13:25:10 +0000
We have given our Drug Tariff Monitor an overhaul, redesigned to operate under the same layout as our therapeutic reports and incorporating more data and we would appreciate any feedback you may have. The draft version of the new report is now available on our website for download (after logging in select ‘Cost Impact and Savings’ and ‘Drug Tariff Monitor’). To provide any feedback, queries or comments about the content of the new report, please do not hesitate to contact us at firstname.lastname@example.org
Published: Thu, 27 Sep 2018 11:55:21 +0000
July 2018 reports are now online. These documents are available to our stakeholders only (username and passowrd required). Access is via the 'Financial Headlines' link in the Prescribing Analysis Reports section of this site.
Published: Thu, 20 Sep 2018 12:43:28 +0000
The latest Prescribing Support Update Newsletter is now online. Topics covered include the safety of DOACs in primary care, analgesia in back and joint pain and new MHRA e-learning on ADRs.
Please see our Update Newsletter page.
Published: Tue, 18 Sep 2018 09:19:01 +0000
Drug Tariff monitors for August 2018 are now online. These documents are available to our stakeholders only (username and password required). Access is via the Prescribing Analysis Reports menu, look for 'Drug Tariff Monitor' under the Cost Impact and Savings submenu.
Published: Wed, 12 Sep 2018 11:44:21 +0000
“Moving Medicine is the single most important advance in therapeutics in my 50 years in medicine. The benefit to harm ratio is outstandingly favourable and every drug or psychological prescription for a long-term condition should be partnered by a Moving Medicine prescription of activity.” Sir Muir Gray Kt CBE DSc MDMemos and Alerts News Prescribing Newsletter
Published: Fri, 19 Oct 2018 17:46:57 +0000
The Home Office has announced plans to classify both gabapentin and pregabalin as Class C controlled drugs in April 2019. The decision to apply Misuse of Drugs act controls to gabapentin and pregabalin is based on advice from the Advisory Council on the Misuse of Drugs – in response to concerns over medicinal misuse, illegal diversion of the drugs and Continue Reading »
The post Gabapentin & Pregabalin – to be Controlled Drugs in 2019 appeared first on NECS Medicines Optimisation.Memos and Alerts News Prescribing Newsletter
Published: Fri, 19 Oct 2018 17:09:40 +0000
The MHRA have authorised ALK to extend the use by dates of specified Lots (Batches) of Jext 150 microgram adrenaline auto-injectors & Jext 300 microgram adrenaline auto-injectors (follow links for Lot/Batch numbers). Please see the JEXT website and DHSC Q&A for full details.
The post Jext Adrenaline Auto-Injectors – Extended Use By Dates appeared first on NECS Medicines Optimisation.Memos and Alerts News Supply Issues_Shortages
Published: Wed, 17 Oct 2018 15:48:28 +0000
The Department of Health & Social Care (DHSC) has put in place a Dispenser Validation process for all prescriptions for 150 microgram adrenaline auto-injectors. The validation process is designed to ensure that all children weighing 25Kg or less have access to two 150 microgram adrenaline auto-injectors and that at least one of these is in-date. DHSC has stated: Continue Reading »
The post Adrenaline 150microgram Auto-injectors – Supply Controls appeared first on NECS Medicines Optimisation.Memos and Alerts News Supply Issues_Shortages
Published: Wed, 17 Oct 2018 10:44:31 +0000
NHS England have issued a Press Release announcing that the NHS is set “to save £150 million by switching to new versions of most costly drug.” NHS Hospitals have been asked “to ensure they are ready to realise savings of up to £150 million a year to reinvest in frontline care after the patent on the NHS’s most costly Continue Reading »
The post NHS England Press Release – Adalimumab Patent Expiry appeared first on NECS Medicines Optimisation.News Prescribing Newsletter
Published: Tue, 16 Oct 2018 16:26:38 +0000
Rivaroxaban treatment in patients who undergo transcatheter aortic valve replacement (TAVR) should be stopped and switched to standard of care.
Monitor thyroid-stimulating hormone (TSH) in patients treated with levothyroxine for at least the first month after starting and ending ritonavir treatment.
Interrupt treatment if posterior reversible encephalopathy syndrome (PRES) is confirmed and resume treatment only once the event is resolved and the benefit of continued treatment outweighs the risk of PRES.
Provide clear information to patients and caregivers about how to minimise the risk of accidental exposure and the importance of appropriate disposal of patches.
A supply disruption alert was issued by the Department of Health & Social Care (DHSC) on EpiPen and EpiPen Junior; see MHRA advice on extension of use beyond the expiry date for certain batches of EpiPen 300 microgram adrenaline autoinjectors.
Alerts were recently issued by MHRA about flex connectors in Halyard closed suction kits; SureSigns VS & VM patient monitors and viewing stations; and Zimmer Biomet trauma guide wires.
Valproate medicines must not be used in women of childbearing potential unless the Pregnancy Prevention Programme is in place.
Now only authorised for use in patients with symptomatic bone metastases and no known visceral metastases who have had 2 previous systemic treatments for metastatic castration-resistant prostate cancer or who cannot receive other systemic treatments.
Monitoring for encephalitis should continue for 12 months following discontinuation of daclizumab.
Advise patients and their caregivers to seek urgent medical attention if any signs or symptoms of communicating hydrocephalus develop during nusinersen therapy for spinal muscular atrophy.
Northern Treatment Advisory Group: http://ntag.nhs.uk/html/latest_news.html